Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds William Blair Upgrades FibroGen to Outperform

William Blair Upgrades FibroGen to Outperform

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

byBenzinga Newsdesk

January 31, 2023

1 minute read

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

McDonald’s Options Traders Betting On Stock Falling By Friday

By Priya Nigam

April 25, 8:13 AM

McDonald's Corporation (NYSE: MCD) shares edged higher on Monday, as the company reported quarterly earnings on Tuesday.

News

Atossa Therapeutics Granted Additional Patent Protection For Endoxifen

By Happy Mohamed

June 21, 10:15 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today

ATOS

Top Wall Street Analyst Warns Of ‘Proper Bust’ In 2023: Stocks Are Trading In ‘High Risk Zone’

By Piero Cingari

June 26, 11:33 AM

A top Wall Street analyst has issued a cautionary note, warning of a potential sharp reversal in the…

IWD

Analyst Ratings

In-Depth Examination Of 5 Analyst Recommendations For Cara Therapeutics

By Benzinga Insights

Today, 12:01 PM

Cara Therapeutics (NASDAQ:CARA) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from…

CARA

William Blair Upgrades FibroGen to Outperform

Related Posts

McDonald’s Options Traders Betting On Stock Falling By Friday

Atossa Therapeutics Granted Additional Patent Protection For Endoxifen

Top Wall Street Analyst Warns Of ‘Proper Bust’ In 2023: Stocks Are Trading In ‘High Risk Zone’

In-Depth Examination Of 5 Analyst Recommendations For Cara Therapeutics